CXCR2CXCR2 as a biomarker and therapeutic target of basal type breast cancer
The present invention relates to a kit for diagnosing a basal-type breast cancer and a method for diagnosing a basal-type breast cancer, wherein the kit measures the expression level of C-X-C Motif Chemokine Receptor 2 (CXCR2) in a sample derived from a breast cancer. In addition, the present invent...
Saved in:
Main Authors | , , |
---|---|
Format | Patent |
Language | English Korean |
Published |
08.03.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present invention relates to a kit for diagnosing a basal-type breast cancer and a method for diagnosing a basal-type breast cancer, wherein the kit measures the expression level of C-X-C Motif Chemokine Receptor 2 (CXCR2) in a sample derived from a breast cancer. In addition, the present invention relates to a pharmaceutical composition for treating a basal-type breast cancer containing a substance that inhibits the expression or activity of CXCR2 or a pharmaceutical composition for inhibiting epithelial-to-mesenchymal transition (EMT) and/or angiogenesis of breast cancer cells.
본 발명은 유방암 유래의 시료 중 CXCR2(C-X-C Motif Chemokine Receptor 2)의 발현 수준을 측정하는 것을 포함하는 기저형(basal type) 유방암 진단용 키트 및 기저형 유방암의 진단방법에 관한 것이다. 또한 본 발명은 CXCR2의 발현 또는 활성을 억제하는 물질을 포함하는 기저형 유방암 치료용 약제학적 조성물 또는 유방암 세포의 상피간엽이행(epithelial-to-mesenchymal transition, EMT) 및/또는 혈관신생 억제용 약제학적 조성물에 관한 것이다. |
---|---|
Bibliography: | Application Number: KR20210116433 |